Biomarkers and translational research and precision medicine

42P_PR - Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study

Authors
  • Sara C. Altuna (Caracas, Venezuela)
  • Csongor Lengyel (Budapest, Hungary)
  • Dario Trapani (Milan, Italy)
  • Essam M. Elfaham (Alexandria, Egypt)
  • Sadaqat Hussain (Riyadh, Saudi Arabia)
  • Angelica Petrillo (Napoli, Italy)
  • Khalid El Bairi (Oujda, Morocco)
  • Syed A. Mazher (Little Rock, United States of America)
  • Baker S. Habeeb (Erbil, Iraq)
  • Shah Zaib Khan (Peshawar, Pakistan)
Speakers
  • Sara C. Altuna (Caracas, Venezuela)

Previous ePoster
40P - WNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells

Next ePosters
43P - CIP2A as a novel target to combat basal like breast cancer
46P - BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience
49P - The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms
50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy
51P - Higher ER load is not associated with better outcome in stage I-III breast cancer
52P - The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC
53P - Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients
54P - Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab
55P - Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome
58P - Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers